Le Lézard
Classified in: Health, Covid-19 virus
Subjects: WOM, MRR

Global Menopause Market Analysis Report 2024, Featuring Profiles of Bayer, Theramex, Abbvie, Abbott, Pure Encapsulations, Dr. Reddy's Laboratories, Rainbow Light and Padagis


DUBLIN, March 20, 2024 /PRNewswire/ -- The "Global Menopause Market Size, Share & Trends Analysis Report by Treatment (Dietary Supplements, OTC Pharma Products), Region (North America, Europe, Latin America), and Segment Forecasts, 2024-2030" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The global menopause market size is expected to reach USD 24.4 billion by 2030, registering a CAGR of 5.37% from 2024 to 2030, according to the report. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.3. Market Trends and Outlook
3.4. Market Dynamics
3.4.1. Growing number of women undergoing menopause
3.4.2. Increasing awareness about menopause and its treatment
3.4.3. Growing opportunities and innovations in menopause treatment
3.4.4. Increasing research supporting advantages of dietary supplements
3.5. Market Restraint Analysis
3.5.1. Social stigma associated with menopause and adverse effects of products
3.5.2. Lack of well-defined regulations
3.6. Business Environment Analysis
3.7. COVID-19 Impact Analysis

Chapter 4. Treatment Business Analysis
4.1. Menopause Market: Treatment Movement Analysis
4.2. Dietary Supplements
4.3. OTC Pharma Products
4.3.2. Hormonal Products
4.3.3. Non-hormonal Products

Chapter 5. Regional Business Analysis
5.1. Menopause Market Share By Region, 2023 & 2030

Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Participant's overview

For more information about this report visit https://www.researchandmarkets.com/r/kngzpx

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

SOURCE Research and Markets


These press releases may also interest you

4 mai 2024
The Better Business Bureau Serving the...

3 mai 2024
CMC Metals Ltd. (CMCXF:OTCQB) ("CMC" or the "Company") announces that as a result of a review by the British Columbia Securities Commission ("BCSC"), the Company is issuing the following news to clarify previous...

3 mai 2024
The Board of Trustees of First Trust Energy Infrastructure Fund (the "Fund") , CUSIP 33738C103, previously approved a managed distribution policy for the Fund (the "Managed Distribution Plan") in reliance on exemptive relief received from the...

3 mai 2024
FGI Industries Ltd. ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced that it will issue financial results for the first quarter 2024 after the market close on Wednesday, May 8, 2024. Management will...

3 mai 2024
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead...

3 mai 2024
University of Phoenix College of Nursing is pleased to highlight the recent publication by alumna Gloria Littlemouse, Ph.D. in Nursing, MSN, RN, WCSI Scholar, whose dissertation study informed an article, "Lived Experiences of ICU Nurses During...



News published on and distributed by: